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Summary
 Background Breast cancer is the most common malignancy for women in Poland and repre-
sents 19.7% of all neoplasms diagnosed in this group. It is also the most frequent 
cause of cancer related deaths among women (14.1% of total).
  An improvement in these results has been achieved by the popularisation of pro-
phylactic mammography. An increase in awareness among women, of the dan-
gers of breast cancer, and an increase in the availability of mammography testing 
has resulted in impalpable breast lesions being diagnosed increasingly frequent-
ly. These diagnoses require histopathological veriﬁ cation.
 Aim To demonstrate the usefulness of stereotactic mammotomy biopsy (SMB)in the 
diagnosis of impalpable breast lesions, and its effects on the processes of diagno-
sis, classiﬁ cation and treatment of pre-invasive growths within the breast.
 Materials/Methods Stereotactic mammotomy biopsy is a minimally invasive method for the collec-
tion of tissue from impalpable changes in the breast which are visible in mam-
mography images and require histopathological diagnosis. The procedure may 
be carried out on an ambulant patients, under a local anaesthetic.
  Between April, 2000, and August, 2003, the First Surgical Department carried out 
2000 SMB procedures. Changes suitable for biopsy fall into three groups: clus-
ters and areas of microcalciﬁ cation – 929 (46.45%), small tumours and soft tis-
sue density – 975 (48.75%), radial structures – 96 (4.80%).
 Results 365 patients (18.25%)required surgery for the purpose of obtaining a histopatho-
logical diagnosis, including 150 (7.50%)with invasive cancer, 120 (6.00%)with pre-
invasive cancer – DCIS and 95 (4.75%)with atypical ductal hyperplasia – ADH.
  Among the remaining 1635 patients (81.75%)changes were found to be benign 
and the patients avoided surgery.
 Conclusions It is demonstrated that stereotactic mammotomy biopsy is the method of choice 
for the diagnosis of mammographically detected, inpalpable lesions of the breast, 
and furthermore, contributes to the process of diagnosis, classiﬁ cation and treat-
ment of pre-invasive growths in the breast.
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BACKGROUND
Breast cancer is the most common malignancy 
for women in Poland and represents 19.7% of 
all neoplasms diagnosed in this group. It is also 
the most frequent cause of cancer related deaths 
among women (14.1% of total).
An improvement in these results has been 
achieved by the popularisation of prophylac-
tic mammography. An increase in awareness 
among women, of the dangers of breast cancer, 
and an increase in the availability of mammog-
raphy testing has resulted in impalpable breast 
lesions being diagnosed increasingly frequent-
ly. These diagnoses require histopathological 
veriﬁ cation.
Methods currently used for the collection of ma-
terial for microscopic analysis include ﬁ ne needle 
aspiration, tru-cut biopsies (under ultrasound or 
mammography guidance)and open surgical bi-
opsies after needle localisation. These methods 
have proven to be disappointing and imperfect. 
There remained a need for a diagnostic meth-
od, of high sensitivity and speciﬁ city, which could 
be performed on ambulant patients, under local 
anaesthetic. In order to meet this need, stereo-
tactic mammotomy biopsies were developed and 
introduced into clinical practice in the United 
States during the 90s. The method was also quick-
ly adopted in Europe.
In Poland there are several facilities working in 
this area, one such facility is in the Great Poland 
Cancer Centre in Poznań.
Patients qualifying for mammotomy biopsy have 
mammographically detected impalpable changes 
in the breast, requiring histopathological veriﬁ -
cation. The change must be of deﬁ ned character 
(clusters or areas of microcalciﬁ cation, small tu-
mours or soft tissue density, radial structures)and 
must be visible in two mammograms.
The mammotomy procedure requires no special 
preparation and may be carried out on ambulant 
patients using a local anaesthetic.
AIM
To demonstrate the usefulness of stereotactic 
mammotomy biopsy (SMB)in the diagnosis of 
impalpable breast lesions, and its effects on the 
processes of diagnosis, classiﬁ cation and treat-
ment of pre-invasive growths within the breast.
MATERIALS AND METHODS
The equipment consists of: a digital mammo-
graph – which produces images of selected ar-
eas of the breast, of size 5×5 cm and of 8 × mag-
niﬁ cation, a stereotactic table with a moveable 
frame which holds a biopsy needle and a com-
puter to control the whole system.
Procedure
The patient is positioned on their stomach on a 
Fischer stereotactic table. The breast to be biopsied 
is positioned at an opening in the table. Based on 
assessment of existing mammograms, the chang-
es are localized and a holding plate with an open-
ing measuring 5×5 cm holds the breast such that 
the changes are in its centre. A radiogram, of 0 
degrees projection, is made and a check is made 
on a monitor screen to ensure that the sought fo-
cus of changes is visible. If not, a further attempt 
is made. If the change is visible, two further radio-
grams are made with projections of (+)15 degrees 
and (–)15 degrees. On screen the result is views of 
the same change through 30 degrees of perspec-
tive. The cursor is used to mark the same point on 
both images. Marking only this single altered ele-
ment guarantees sampling of the proper materi-
al. Further procedures leading to the choice of pa-
rameters of the biopsy are made by the computer 
programs and are shown on the horizontal, verti-
cal and depth axes of the on-screen display. The 
horizontal and vertical axes are automatically in-
troduced into the device guiding the biopsy nee-
dle. The depth to which the needle is to be insert-
ed into the immobilized breast is determined, by 
the surgeon, on a scale on the guidance device and 
in accordance with indications from the computer. 
The invasive part of the method follows. The frag-
ment of skin visible in the window of the guide plate 
is disinfected. The area where the needles are to 
be introduced is anaesthetised using 1% Xylocaine 
with Adrenalin and the skin is incised to a length 
of 3 to 5 mm. The biopsy needle is introduced to 
the breast, to the depth indicated on the guide 
scale. In this position, the tip of the needle touch-
es the determined target. After the blockade is re-
moved, the trigger button is pushed and we make 
a “shot” which introduces the needle in such a way 
that the biopsy chamber will be in the area of the 
change. The collected material, which consists of 
10–30 cylinders of tissue (30–100 mg of tissue), is 
withdrawn by around 1 cm using a clockwise and 
outward motion. After the collection of material 
is completed, we make images of the area in or-
der to assess the extent of tissue removal. The site 
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of the biopsy may be marked using special metal 
clips. Before the removal of the biopsy needle, the 
area is evacuated. After the procedure, the patient 
is laid on their back and is asked to hold gauze 
against the injury site for 10 minutes. The injury 
is then stuck with ‘steri-strip’ and bound up with 
compression to protect it for a further 24 hours. 
After a week, during follow-up, the patient is in-
formed of the results of the histopathological in-
vestigation and is offered recommendations.
Between April, 2000, and August, 2003, the 
Mammotomy Suite within I st Surgical Department, 
Great Poland Cancer Centre, Poznań, carried out 
2000 mammotomy procedures.
RESULTS
In our material the dominating changes were 
masses, together there were 975 (48.75%)of such 
cases. Among these we differentiated a group of 
changes accompanied by macro, micro and mixed 
forms of calciﬁ cation, in total 293 cases (14.65%). 
The second largest group was microcalciﬁ cation, 
in total 929 cases (46.45%). Among these, 504 
(25.20%)were small clusters which could be 
completely removed and 425 (21.25%)with ar-
eas from which samples were taken. The least 
common changes were radial structures – 96 cas-
es (4.80%) (Table1).
150 invasive cancers were diagnosed, as well as 120 
cases of DCIS and 95 cases of ADH. These patients 
underwent further surgical treatment. Also detected 
were 16 cases of LCIS, and the patients, as a group 
at increased risk of malignant invasion, were quali-
ﬁ ed for close oncological observation (Table 2).
Amongst 270 patients operated for breast can-
cer, diagnosed by mammotomy biopsy, the 
Table 1. Radiological character of lesions undergoing SMB.
Radiological 












Number  504  425  682  293  96
Percentage [%]  25.20  21.25  34.10  14.65  4.80
Number operated Invasive cancer DCIS ADH
365  150  120  95
Percentage operated [%]  41.10  32.88  26.03
Table 2. Amount of histopathological changes which required surgical treatment.
Type of surgical treatment DCIS Ca duct.invasiv.
Ca lobul. 
invasiv. ADH Total
Radical mastectomy  32  79  29 –  140
Mastectomy with the fi rst fl oor lymph nodes  11 – – –  11
Simple mastectomy + SNB  28 – – –  28
BCT + RADICAL LYMPHADENECTOMY + RADIATION  7  41  1 –  49
BCT + SNB + RADIATION  7 – – –  7
BCT + SNB  35 – – –  35
Wide excision – – –  95  95
Table 3. Comparison of applied surgical procedures.
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breast was saved in 90 cases (33.33%). In 70 cas-
es (25.93%)the axillary lymph nodes were saved, 
and in 11 cases (4.07%)only ﬁ rst ﬂ oor of the ax-
illary lymph nodes was removed.
In 95 cases a diagnosis of ADH resulted in wide 
excision, protecting the patient from histologi-
cal progression and development of a malignant 
tumour (Table 3).
In the remaining 1635 patients, in whom benign 
changes were diagnosed, thanks to minimally in-
vasive method, unnecessary surgical treatment 
was avoided. In 981 cases the change, veriﬁ ed 
as mild, was removed radical in mammotomy, 
which saved the patients from worry and onco-
logical control.
DISCUSSION
Malignant tumours of the breast are the most 
common cause of early death amongst women 
from the world’s developed countries [1–3].
While many factors that increase the risk of ma-
lignancy have been described, many early preven-
tion possibilities remain unknown. Early diagnosis 
and the earliest possible treatment are deﬁ nitely 
signiﬁ cant in the ﬁ ght against breast cancer. In 
Scandinavia it was found that such an approach 
may reduce mortality by as much as 20–30%. In 
Poland, since the 1940s, factors that led to mor-
tality from breast cancer had remained stable but, 
since 1980, these factors have been further slowed 
and have stabilised. This tendency falls into the 
same time period as the development, and growth 
in popularity, of mammography tests [4–6].
The popularisation of prophylactic mammogra-
phy has been helpful in the diagnosis of non-pal-
pable changes within the breast. In the literature 
it is noted that as many as 20% of such cases def-
initely require surgical intervention as they are 
pre-cancerous states, pre-invasive malignancies 
and invasive malignancies and our test material 
has conﬁ rmed this ﬁ nding. Patients in whom very 
small and non-invasive changes were identiﬁ ed 
have the greatest chances for full recovery and 
have improved the applicable statistics [1–3].
A new problem concerning the veriﬁ cation of 
on-screen testing arose. The existing methods 
used for the collection of tissue for microscop-
ic analysis proved to be unreliable. In the ﬁ rst 
place, material must be collected after visual lo-
calization of the change: by ultrasonography if 
the change is visible in ultrasound images or by 
mammography if the change is visible only in 
mammograms.
Secondly, cytological material in very early chang-
es proved to be insufﬁ cient for differentiation and 
for giving a therapeutic diagnosis [7–11].
Until now, the collection of such changed materi-
al for histopathological analysis required a surgi-
cal procedure and a general anaesthetic. An open 
biopsy was performed in which a fairly large por-
tion of the mammary gland was removed (from 
20 to 250g of tissue). The siting of the biopsy was 
orientated on the basis of mammography images 
in two projections or on the basis of a previously 
installed J-needle. Intra-operative radiograms con-
ﬁ rmed the presence of any pathological change in 
the material. In the event that the expected chang-
es were not found in the sample, the area of exci-
sion was widened. This method required hospital-
isation of the patient in order to prepare for the 
procedure, and a general anaesthetic. This approx-
imate localization method required the removal 
of too large a fragment of breast tissue which of-
ten led to imperfect cosmetic effects and some-
times to local complications such as haematoma 
or inﬂ ammation of the wound.
Based on both, the statistics and from our mate-
rial, around 80% of veriﬁ ed impalpable lesions 
are benign and do not require such an exten-
sive procedure.
With the increase of mammographically detect-
ed impalpable breast lesions and with improve-
ment of sampling methods for the collection of 
material for histopathology analysis, a new prob-
lem concerning differentiation and classiﬁ cation 
of borderline changes arose.
As it turned out, this is a very heterogeneous 
group and many factors must be properly de-
ﬁ ned in order to predict the disease process and 
appropriate therapy [12,13].
In the pre-mammography era, the proportion 
of DCIS cases amounted to 1% of newly discov-
ered breast cancers. Presently, in the United 
States, it amounts to 17% of all newly diagnosed 
breast cancers and 40% of all impalpable breast 
lesions [14,15].
In our material, 120 cases of DCIS were diag-
nosed, amounting to 44.44% of all cancers rec-
ognized in the biopsy material.
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Stereotactic mammotomy biopsy is a very efﬁ cient, 
modern and safe method, for both personnel and 
patients, for the collection of material for microscop-
ic analysis of impalpable changes in the breast.
The procedure should be carried out in a special-
ist oncology unit which can guarantee assessment 
of the biopsy material, by a histopathologist with 
experience of breast disease, and which is able to 
offer further complex treatment where need be.
As the procedure has become more popular in 
the United States, in Western Europe and now in 
Poland, it has become the method of choice for 
the diagnosis of impalpable lesions of the mam-
mary glands [8,9,16–19].
The borderline character of discovered changes 
and their frequency in biopsy material has helped 
to deﬁ ne the size of the problem and has driv-
en development of histopathological assessment 
and new systems of classiﬁ cation.
CONCLUSIONS
1. SMB is an efﬁ cient and the least invasive meth-
od of all heretofore use methods of obtaining 
tissue mass for histopathological veriﬁ cation in 
impalpable lesions in the mammary gland.
2.  SMB makes it possible to avoid operation for 
approximately 80% of patients subjected to bi-
opsy, while for 20% of them enables accurate 
diagnosis and application of proper and most 
favourable treatment.
3.  SMB allows veriﬁ cation of very early changes in 
the breast, offering a chance for complete re-
covery with a limited and sparing operation.
4.  SMB aids development in the area of diagno-
sis, classiﬁ cation and treatment of borderline 
lesions in the breast.
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